Cancer metabolism: Strategic diversion from targeting cancer drivers to targeting cancer suppliers

Biomolecules and Therapeutics

Volumn 23, Issue 2, 2015, Pages 99-109

  Kim, Soo Youl ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CRIZOTINIB; CYCLOPHOSPHAMIDE; DASATINIB; ERLOTINIB; ETHINYLESTRADIOL; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; MERCAPTOPURINE; METFORMIN; METHOTREXATE; NILOTINIB; PAZOPANIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THIOTEPA; UNINDEXED DRUG; URAMUSTINE; VEMURAFENIB; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BIOENERGY; BIOSYNTHESIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL HETEROGENEITY; CHRONIC MYELOID LEUKEMIA; DIABETES MELLITUS; DRUG TARGETING; GENOMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT;

EID: 84923637078     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.013     Document Type: Article

References (53)

1. Arduino, L. J. and Mellinger, G. T. (1967) Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother. Rep.51, 295-303.
2. Armour, A. A. and Watkins, C. L. (2010) The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur. Respir. Rev.19, 186-196.
3. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y. and Bost, F. (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene27, 3576-3586.
4. Bernards, R. (2012) A missing link in genotype-directed cancer therapy. Cell151, 465-468.
5. Birsoy, K., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., Brummelkamp, T. R., Clish, C. B. and Sabatini, D. M. (2013) MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat. Genet.45, 104-108.
6. Brook, J., Bateman, J. R. and Steinfeld, J. L. (1964) Evaluation of Melphalan (Nsc-8806) in Treatment of Multiple Myeloma. Cancer Chemother. Rep.36, 25-34.
7. Buck, E., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P. and Iwata, K. K. (2006) Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther.5, 2051-2059.
8. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature490, 61-70.
9. Chabner, B. A. and Roberts, T. G., Jr. (2005) Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer5, 65-72.
10. Chan, S. (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer91, 1420-1424.
11. Cheong, H., Lu, C., Lindsten, T. and Thompson, C. B. (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol.30, 671-678.
12. DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S. and Thompson, C. B. (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. U.S.A.104, 19345-19350.
13. Edmonson, J. H., Lagakos, S., Stolbach, L., Perlia, C. P., Bennett, J. M., Mansour, E. G., Horton, J., Regelson, W., Cummings, F. J., Israel, L., Brodsky, I., Shnider, B. I., Creech, R. and Carbone, P. P. (1976) Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung. Cancer Treat. Rep.60, 625-627.
14. Ertmer, A., Huber, V., Gilch, S., Yoshimori, T., Erfle, V., Duyster, J., Elsasser, H. P. and Schatzl, H. M. (2007) The anticancer drug imatinib induces cellular autophagy. Leukemia21, 936-942.
15. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. and Morris, A. D. (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ330, 1304-1305.
16. Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B. and Rabinowitz, J. D. (2014) Quantitative flux analysis reveals folatedependent NADPH production. Nature510, 298-302.
17. Fausel, C. (2007) Targeted chronic myeloid leukemia therapy: Seeking a cure. Am. J. Health Syst. Pharm.64, S9-15.
18. Fisher, B. K. and Elliott, G. B. (1965) Triple drug therapy with actinomycin D (Nsc-3053), chlorambucil (Nsc-3088), and methotrexate (Nsc-740) in metastatic solid tumors in children. Cancer Chemother. Rep.45, 45-51.
19. Foley, J. F. and Kennedy, B. J. (1964) Effect of cyclophosphamide (Nsc-26271) on far-advanced neoplasia. Cancer Chemother. Rep.34, 55-58.
20. Gilman, A. (1963) The initial clinical trial of nitrogen mustard. Am. J. Surg.105, 574-578.
21. Goldman, J. M. and Melo, J. V. (2003) Chronic myeloid leukemia--advances in biology and new approaches to treatment. N. Engl. J. Med.349, 1451-1464.
22. Gorzalczany, Y., Gilad, Y., Amihai, D., Hammel, I., Sagi-Eisenberg, R. and Merimsky, O. (2011) Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. Cancer Lett. 310, 207-215.
23. Haugrud, A. B., Zhuang, Y., Coppock, J. D. and Miskimins, W. K. (2014) Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. Breast Cancer Res. Treat.147, 539-550.
24. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
25. Jackson, R. C. (1987) Unresolved issues in the biochemical pharmacology of antifolates. NCI Monogr. 9-15.
26. Jacobs, E. M., Peters, F. C., Luce, J. K., Zippin, C. and Wood, D. A. (1968) Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA203, 392-398.
27. Janku, F., McConkey, D. J., Hong, D. S. and Kurzrock, R. (2011) Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol.8, 528-539.
28. Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M. C., Hortobagyi, G. N. and Gonzalez-Angulo, A. M. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol.27, 3297-3302.
29. Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y. and Kondo, S. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11, 448-457.
30. Kimura, T., Takabatake, Y., Takahashi, A. and Isaka, Y. (2013) Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73, 3-7.
31. Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A. and Adeli, K., et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy8, 445-544.
32. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C. and Baldwin, J., et al. (2001) Initial sequencing and analysis of the human genome. Nature409, 860-921.
33. Lottmann, H. B., Margaryan, M., Bernuy, M., Rouffet, M. J., Bau, M. O., El-Ghoneimi, A., Aigrain, Y., Stenberg, A. and Lackgren, G. (2002) The effect of endoscopic injections of dextranomer based implants on continence and bladder capacity: a prospective study of 31 patients. J. Urol.168, 1863-1867.
34. Michelakis, E. D., Webster, L. and Mackey, J. R. (2008) Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer99, 989-994.
35. Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., Yamada, S. D., Peter, M. E., Gwin, K. and Lengyel, E. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med.17, 1498-1503.
36. Regelson, W., Holland, J. F., Frei, E., 3rd, Gold, G. L., Hall, T., Krant, M. and Miller, S. O. (1964) Comparative clinical toxicity of 6-mercaptopurine (Nsc-755)-1 and 6-mercaptopurine ribonucleoside (Nsc-4911)-2 administered intravenously to patients with advanced cancer. Cancer Chemother. Rep.36, 41-48.
37. Robinson, M. M., McBryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C. and Curthoys, N. P. (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J.406, 407-414.
38. Sausville, E. A. and Johnson, J. I. (2000) Molecules for the millennium: how will they look? New drug discovery year 2000. Br. J. Cancer83, 1401-1404.
39. Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., Dang, C. V. and Riggins, G. J. (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981-8987.
40. Sonveaux, P., Copetti, T., De Saedeleer, C. J., Vegran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frerart, F., Gallez, B., Ribeiro, A., Michiels, C., Dewhirst, M. W. and Feron, O. (2012) Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PloS One7, e33418.
41. Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O. and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest.118, 3930-3942.
42. Sooparb, S., Price, S. R., Shaoguang, J. and Franch, H. A. (2004) Suppression of chaperone-mediated autophagy in the renal cortex during acute diabetes mellitus. Kidney Int. 65, 2135-2144.
43. Spear, B. B., Heath-Chiozzi, M. and Huff, J. (2001) Clinical application of pharmacogenetics. Trends Mol. Med.7, 201-204.
44. Stegmeier, F., Warmuth, M., Sellers, W. R. and Dorsch, M. (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther.87, 543-552.
45. Strausberg, R. L., Simpson, A. J., Old, L. J. and Riggins, G. J. (2004) Oncogenomics and the development of new cancer therapies. Nature429, 469-474.
46. Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B. and Kondo, S. (2005) Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65, 3336-3346.
47. Vander Heiden, M. G. (2011) Targeting cancer metabolism: a therapeutic window opens. Nature reviews. Nat. Rev. Drug Discov.10, 671-684.
48. Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J. and Sutton, G. G., et al. (2001) The sequence of the human genome. Science291, 1304-1351.
49. Ward, P. S. and Thompson, C. B. (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell21, 297-308.
50. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther.7, 3129-3140.
51. Yun, M., Bang, S. H., Kim, J. W., Park, J. Y., Kim, K. S. and Lee, J. D. (2009) The importance of acetyl coenzyme A synthetase for 11Cacetate uptake and cell survival in hepatocellular carcinoma. J. Nucl. Med.50, 1222-1228.
52. Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N. and Pollak, M. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273.
53. Zhao, Y., Liu, H., Riker, A. I., Fodstad, O., Ledoux, S. P., Wilson, G. L. and Tan, M. (2011) Emerging metabolic targets in cancer therapy. Front. Biosci.16, 1844-1860.